摘要
目的观察丹红注射液治疗急性冠脉综合征(ACS)的疗效以及治疗前后的血清超敏C-反应蛋白(hs-CRP)水平的动态变化,初步探讨其对血清hs-CRP的影响及可能的机制。方法将60例ACS患者随机均分为丹红注射液治疗组和常规治疗组,各30例。丹红注射液治疗组另外加用丹红注射液(20mg/d)治疗,疗程均为14d。同时收集20名同期健康体检者,取其血清作为正常对照组。结果 (1)治疗前,ACS患者血清hs-CRP水平明显高于正常对照组(P<0.05);(2)治疗后,丹红注射液治疗组与常规治疗组治疗总有效率分别为96.67%与73.33%(P<0.05),2组ACS患者血清hs-CRP水平较治疗前都有降低(P<0.05),但丹红注射液治疗组比常规治疗组降低更明显(P<0.05);(3)2组ACS患者未出现药物不良反应。结论丹红注射液治疗ACS安全、有效,可显著降低ACS患者血清hs-CRP水平,抑制冠脉炎症反应。
Objective To investigate the effect of Danhong injection on serum hs--CRP in patients with ACS.Methods Sixty patients with ACS were randomly divided into therapy group （Danhoug injection set） and control group with thirty cases in each.Results After treatment, The total effective rates were 96.67% in therapy group and 73.33% in control group（P〈0.05）.Compared with control group,the lever serum hs--CRP decreased obviously in therapy group（P〈0.05）.There was no adverse reaction in both groups.Conclusion Danhong injection therapy is effective and safe for patients with ACS. It can inhibit the inflammation of coronary arteries.
出处
《中国卫生产业》
2011年第10Z期11-12,共2页
China Health Industry
关键词
急性冠脉综合征
丹红注射液
超敏C-反应蛋白
Acute coronary syndromes
Danhong injection
High sensitivity C--reactive protein
